Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators
- PMID: 15289350
- DOI: 10.1158/0008-5472.CAN-04-0377
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators
Abstract
Patients with disseminated Ewing's family of tumors (ESFT) often experience drug-resistant relapse. We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse. We determined the following: (a) 4-HPR cytotoxicity against 12 ESFT cell lines in vitro; (b) whether 4-HPR increased ceramide species (saturated and desaturated ceramides); (c) whether physiological hypoxia (2% O(2)) affected cytotoxicity, mitochondrial membrane potential (DeltaPsi(m)) change, or ceramide species or reactive oxygen species levels; (d) whether cytotoxicity was enhanced by l-threo-dihydrosphingosine (safingol); (e) whether physiological hypoxia increased acid ceramidase (AC) expression; and (f) the effect of the AC inhibitor N-oleoyl-ethanolamine (NOE) on cytotoxicity and ceramide species. Ceramide species were quantified by thin-layer chromatography and scintillography. Cytotoxicity was measured by a fluorescence-based assay using digital imaging microscopy (DIMSCAN). Gene expression profiling was performed by oligonucleotide array analysis. We observed, in 12 cell lines tested in normoxia (20% O(2)), that the mean 4-HPR LC(99) (the drug concentration lethal to 99% of cells) = 6.1 +/- 5.4 microm (range, 1.7-21.8 microm); safingol (1-3 microm) synergistically increased 4-HPR cytotoxicity and reduced the mean 4-HPR LC(99) to 3.2 +/- 1.7 microm (range, 2.0-8.0 microm; combination index < 1). 4-HPR increased ceramide species in the three cell lines tested (up to 9-fold; P < 0.05). Hypoxia (2% O(2)) reduced ceramide species increase, DeltaPsi(m) loss, reactive oxygen species increase (P < 0.05), and 4-HPR cytotoxicity (P = 0.05; 4-HPR LC(99), 19.7 +/- 23.9 microm; range, 2.3-91.4). However, hypoxia affected 4-HPR + safingol cytotoxicity to a lesser extent (P = 0.04; 4-HPR LC(99), 4.9 +/- 2.3 microm; range, 2.0-8.2). Hypoxia increased AC RNA expression; the AC inhibitor NOE enhanced 4-HPR-induced ceramide species increase and cytotoxicity. The antioxidant N-acetyl-l-cysteine somewhat reduced 4-HPR cytotoxicity but did not affect ceramide species increase. We conclude the following: (a) 4-HPR was active against ESFT cell lines in vitro at concentrations achievable clinically, but activity was decreased in hypoxia; and (b) combining 4-HPR with ceramide modulators synergized 4-HPR cytotoxicity in normoxia and hypoxia.
Similar articles
-
Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.J Natl Cancer Inst. 2000 Dec 6;92(23):1897-909. doi: 10.1093/jnci/92.23.1897. J Natl Cancer Inst. 2000. PMID: 11106681
-
Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.J Natl Cancer Inst. 2008 Apr 16;100(8):580-95. doi: 10.1093/jnci/djn076. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398104
-
Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46. doi: 10.1093/jnci/91.13.1138. J Natl Cancer Inst. 1999. PMID: 10393722
-
Ceramide synthesis and metabolism as a target for cancer therapy.Cancer Lett. 2004 Apr 8;206(2):169-80. doi: 10.1016/j.canlet.2003.08.034. Cancer Lett. 2004. PMID: 15013522 Review.
-
Ewing's sarcoma and primitive neuroectodermal family of tumors.Hematol Oncol Clin North Am. 2005 Jun;19(3):501-25, vi-vii. doi: 10.1016/j.hoc.2005.03.004. Hematol Oncol Clin North Am. 2005. PMID: 15939194 Review.
Cited by
-
Induction of Mitochondrial Pathways and Endoplasmic Reticulum Stress for Increasing Apoptosis in Ectopic and Orthotopic Neuroblastoma Xenografts.J Cancer Ther. 2011 Jun;2(2):77-90. doi: 10.4236/jct.2011.22009. J Cancer Ther. 2011. PMID: 22468231 Free PMC article.
-
Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.Pharmaceutics. 2024 Apr 24;16(5):579. doi: 10.3390/pharmaceutics16050579. Pharmaceutics. 2024. PMID: 38794242 Free PMC article. Review.
-
N-(4-Hydroxyphenyl) Retinamide Potentiated Anti-tumor Efficacy of Genistein in Human Ewing's Sarcoma Xenografts.World J Oncol. 2011 Apr;2(2):53-63. doi: 10.4021/wjon301w. World J Oncol. 2011. PMID: 21822457 Free PMC article.
-
Inhibition of Colon Cancer Cell Growth by Imidazole Through Activation of Apoptotic Pathway.Med Sci Monit. 2019 Oct 10;25:7597-7604. doi: 10.12659/MSM.917779. Med Sci Monit. 2019. PMID: 31597910 Free PMC article.
-
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.Nature. 2019 Aug;572(7771):676-680. doi: 10.1038/s41586-019-1472-0. Epub 2019 Aug 7. Nature. 2019. PMID: 31391581 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials